REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.01.08 | 07:15 | Permanent Information Releases / General Company News

puce Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease - HTML (w)

2019.01.07 | 23:02 | Permanent Information Releases / General Company News

puce Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder - HTML (w)

2018.12.21 | 14:53 | Permanent Information Releases / General Company News

puce Novartis successfully completes acquisition of Endocyte - HTML (w)

2018.12.20 | 17:00 | Permanent Information Releases / General Company News

puce Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies - HTML (w)

2018.12.20 | 07:00 | Permanent Information Releases / Appointments

puce Novartis announces new CEO of Oncology Business Unit - HTML (w)

2018.12.19 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises - HTML (w)

2018.12.19 | 07:10 | Permanent Information Releases / General Company News

puce Alcon Announces Acquisition of Tear Film Innovations, Inc. - HTML (w)

2018.12.13 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives European Commission approval for self-administration of Xolair® across all indications - HTML (w)

2018.12.10 | 21:42 | Permanent Information Releases / General Company News

puce Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder - HTML (w)

2018.12.08 | 14:00 | Permanent Information Releases / General Company News

puce Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease - HTML (w)

2018.12.06 | 16:30 | Permanent Information Releases / General Company News

puce Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses - HTML (w)

2018.12.03 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1 - HTML (w)

2018.12.02 | 16:15 | Permanent Information Releases / General Company News

puce Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies - HTML (w)

2018.12.01 | 20:30 | Permanent Information Releases / General Company News

puce Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers - HTML (w)

2018.12.01 | 16:15 | Permanent Information Releases / General Company News

puce Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1163